Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction

Summary

Hypothesis: Based on available pharmacokinetic data from healthy volunteers we hypothesize that the administration of a cumulative dose of 210μg of the continuous erythropoietin receptor activator, Mircera® (Roche), during 3 months post percutaneous coronary intervention (PCI) does not result in hemoglobin (Hb) levels \>15 g/dl in patients with ST-segment elevation myocardial infarction (STEMI) Design: Prospective, open label single center pilot study

Timeline

Start

2010-04

Primary completion

2010-09

Completion

2010-10

Drugs

Indications